Preparation and in vivo Assessment of Nystatin-Loaded Solid Lipid Nanoparticles for Topical Delivery against Cutaneous Candidiasis

Authors: Rawia M. Khalil, Ahmed A. Abd El Rahman, Mahfouz A. Kassem, Mohamed S. El Ridi, Mona M. Abou Samra, Ghada E. A. Awad, Soheir S. Mansy

Abstract:

Solid lipid nanoparticles (SLNs) have gained great attention for the topical treatment of skin associated fungal infection as they facilitate the skin penetration of loaded drugs. Our work deals with the preparation of nystatin loaded solid lipid nanoparticles (NystSLNs) using the hot homogenization and ultrasonication method. The prepared NystSLNs were characterized in terms of entrapment efficiency, particle size, zeta potential, transmission electron microscopy, differential scanning calorimetry, rheological behavior and in vitro drug release. A stability study for 6 months was performed. A microbiological study was conducted in male rats infected with Candida albicans, by counting the colonies and examining the histopathological changes induced on the skin of infected rats. The results showed that SLNs dispersions are spherical in shape with particle size ranging from 83.26±11.33 to 955.04±1.09 nm. The entrapment efficiencies are ranging from 19.73±1.21 to 72.46±0.66% with zeta potential ranging from -18.9 to -38.8 mV and shear-thinning rheological Behavior. The stability studies done for 6 months showed that nystatin (Nyst) is a good candidate for topical SLN formulations. A least number of colony forming unit/ ml (cfu/ml) was recorded for the selected NystSLN compared to the drug solution and the commercial Nystatin® cream present in the market. It can be fulfilled from this work that SLNs provide a good skin targeting effect and may represent promising carrier for topical delivery of Nyst offering the sustained release and maintaining the localized effect, resulting in an effective treatment of cutaneous fungal infection.

Keywords: Candida infections, Hot homogenization, Nystatin, Solid lipid nanoparticles, Stability, Topical delivery.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1094203

References:

[1] Muller RH, Mader K, Gohla S, Solid lipid nanoparticles (SLN) for controlled drug delivery- A review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
[2] Radomska-Soukharev A, Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deli Rev 2007; 59: 411-418.
[3] Quinones D, Evone MS, Ghaly S, Formulation and characterization of nystatin gel. PRHSJ 2008; 27: 62.
[4] Sandri G, Bonferoni MC, Gokce EH, Ferrari F, Rossi S, Patrini M, Caramella C, Chitosan associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J Of Microencapsulation 2010; 27: 735-746.
[5] Sharma A, Jindal M, Aggarwal G, Jain S, and Development of a novel method for fabrication of solid lipid nanoparticles: using high shear homogenization and ultrasonication. RJPBCS 2010; 1: 266.
[6] Ekambaram PA, Abdul Hassan Sathali K, Priyanka, Solid lipid nanoparticles: A review. Scientific Reviews & Chemical Communications 2012; 2: 82-85.
[7] Gohla SH, Dingler A, Scaling up feasibility of the production of solid lipid nanoparticles (SLN). Pharmazie 2001; 56: 61-63.
[8] Souto EB, Wissing SA, Barbosa CM, Muller RH, Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004; 278:71.
[9] Jifu H, Xinsheng F, Yanfang Z, Jianzhu W, Fengguang G, Fei L, Xinsheng P, Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. International journal of nanomedecine 2011; 6: 683-692.
[10] Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ, Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999; 59:299.
[11] Esposito E, Bortolotti F, Menegatti E, Cortesi R, Amphiphilic association systems for amphoterecin B delivery. Int J Pharm 2003; 260:249-260.
[12] Ferrer J. Vaginal candidosis: epidemiological and etiological factors. Int J Gynaecol Obstet 2000; 71:21-27.
[13] Wells JI. Pharmaceutical formulations: The physicochemical properties of drug substances. England: Ellis Hortwood, Chichester, 1988:
[14] Maebashi K, Toyama T, Uchida K, Yamaguchi H, A novel model of cutaneous candidiasis produced in prednisolone treated guinea pigs. J Med Vet Mycol. 1995; 19:390-392.
[15] Masson P, Some histological methods. Trichrome staining and their preliminary technique. Bulletin of the International Association of Medicine. 1929; 12: 75.
[16] Abdelbary G, Fahmy RH, Diazepam loaded solid lipid nanoparticles: design and characterization. AAPS Pharm Sci Tech 2009; 10: 215.
[17] Vijayan V, Srinivasa D, Jayachandran E, Anburaj J, Preparation and characterization of anti diabetic drug loaded solid lipid nanoparticles. JITPS 2010; 8: 324.
[18] Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E, Pseudolatex preparation using a novel emulsion-diffusion process involving direct displacement of partially water-miscible solvents by distillation. Int J Pharm 1999; 188: 155-164.
[19] Rahman Z, Zidan AS, Khan MA, Non destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Sci 2010; 76: 127-137.
[20] Yang Y, Chung T, Bai X, Chan W, Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double emulsion method. Chem Eng Sci 2000; 55: 2223-2236.
[21] Ekambaram, P. and Hasan, S.A. Formulation and evaluation of solid lipid nanoparticles of ramipril. J. Young Pharm., 2011; 3:216-220.
[22] Jifu H, Xinsheng F, Yanfang Z, Jianzhu W, Fengguang G, Fei L, and Xinsheng P, Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a box-Behnken design. Int J Nanomedicine 2011; 6:687.
[23] Das S, Ng WK, Tan RBH, Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Europ J Pharm Sci. 2012; 47: 139-151.
[24] Plasencia, I., Norlen, L. and Bagatolli, L.A. Direct visualization of lipid domains in human skin stratum corneum’s lipid membranes: Effect of pH and temperature. Biophys. J.2007; 93, 3142-3155.
[25] Das S, Ng WK, Kanaujia P, kim S, Tan RB, Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces 2011;88:483-489
[26] Illing, A. and Unruh, T. Investigation on the flow behavior of dispersions of solid triglyceride nanoparticles. Int.J.Pharm.2004; 284,123-131.
[27] Liu J., Gong, T., Fu, H., Wang, C., Wang, X., Chen, Q., Zhang, Q., He, Q. and Zhang, Z. Solid lipid nanoparticles for pulmonary delivery of insulin. Int.J.Pharm.2008; 356, 333-344.
[28] Venkateswarlu, V. and Manjunath, K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release, (2004), 95,627-638.
[29] Heiati H , Tawashi R, Shivers RR, Solid lipid nanoparticles as drug carriers I. Incorporation and retention of the lipophilic prodrug 3’- azido-3’deaxythymidine palmitate. Int J Pharm 1997; 146:123-31.
[30] Muller RH, Radtke M, Wissing SA, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 1:131-55.
[31] Pravin P, Anil KS, Subhash CD, Vijay KS, Development of solid lipid nanoparticles of lamivudine for brain targeting. Int J Drug Deliv Tech 2009; 1: 36-38.
[32] Fang JY, Fang CL, Liu CH, SU YH, Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008; 70: 633-640.
[33] Sivaramakrishnan R, Nakamura C, Mehnert W, Korting HC, Kramer KD, Schafer-Korting M, Glucocorticoid entrapment into lipid carriers-characterization by parelectric spectroscopy and influence on dermal uptake. J Control Release. 2004; 97: 493-502.
[34] Gupta M, Vyas SP, Development, characterization and in vivo assessment of effective lipid nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chemistry and Physics of Lipids. 2012; 165: 460.
[35] Amany, M.M. Histological and immunohistochemical study on the effect of tretinoin on the skin of adult male albino rt. Egypt.J.Histol.2008; 31:208-219.